AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16269589 — intervention group
Group type: EXPERIMENTAL
Intervention: PAF group
Number of subjects: 0
Study 12043306 — intervention group
Group type: EXPERIMENTAL
Intervention: Moraxella catarrhalis isolated in patients with bronchial asthma
Number of subjects: 0
Study 12043306 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial flora of the upper respiratory tract in patients with bronchial asthma
Number of subjects: 0
Study 12043306 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida isolation in asthmatics
Number of subjects: 0
Study 12043306 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial tree secretion as diagnostic material
Number of subjects: 0
Study 10541326 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational mammary gland specimens
Number of subjects: 0
Study 10541326 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory specimens
Number of subjects: 0
Study 10541326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactating adenoma
Number of subjects: 0
Study 10541326 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecomastia
Number of subjects: 0
Study 10541326 — intervention group
Group type: COMPARATOR
Intervention: Normal resting breast
Number of subjects: 0
Study 7596933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole, 400 mg/day
Number of subjects: 70
Study 7596933 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 70
Study 2351027 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management training (SMT)
Number of subjects: 36
Study 2351027 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 36
Study 2351027 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 36
Study 484644 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaprox (1,100 mg)
Number of subjects: 24
Study 484644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30068215 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut inclusion (56 g of walnuts daily for 6 months)
Number of subjects: 112
Study 28441618 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use (alcohol and illicit drugs)
Number of subjects: 1434
Study 28441618 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of motivation
Number of subjects: 1434
Study 28441618 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance using patients
Number of subjects: 1434
Study 28441618 — intervention group
Group type: EXPERIMENTAL
Intervention: Any substance, alcohol, and cannabis use
Number of subjects: 1434
Study 26545912 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART intervention
Number of subjects: 58
Study 26545912 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 58
Study 25380344 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% typified propolis rinse
Number of subjects: 42
Study 25380344 — intervention group
Group type: COMPARATOR
Intervention: 0.05% sodium fluoride plus 0.05% cetylpyridinium chloride rinse (positive control)
Number of subjects: 42
Study 22540330 — intervention group
Group type: EXPERIMENTAL
Intervention: STICA treatment (manualized short-term treatment of IA/CA)
Number of subjects: 0
Study 22540330 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 0
Study 19944393 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial radiofrequency ablation (RFA)
Number of subjects: 43
Study 19944393 — intervention group
Group type: COMPARATOR
Intervention: Valvular surgery alone (Control)
Number of subjects: 43
Study 17659455 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition MCT enteral nutrition
Number of subjects: 0
Study 17659455 — intervention group
Group type: COMPARATOR
Intervention: Nutrition MF enteral nutrition
Number of subjects: 0
Study 16481908 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.1 mmol/kg bw)
Number of subjects: 12
Study 16481908 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.1 mmol/kg bw)
Number of subjects: 12
Study 16481908 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.2 mmol/kg bw)
Number of subjects: 12
Study 16481908 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.2 mmol/kg bw)
Number of subjects: 12
Study 12216561 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer cement
Number of subjects: 0
Study 12216561 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement 1
Number of subjects: 0
Study 12216561 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement 2
Number of subjects: 0
Study 9700889 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidumbacterin and carbolen
Number of subjects: 0
Study 7638220 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired training session
Number of subjects: 12
Study 7638220 — intervention group
Group type: COMPARATOR
Intervention: Control session (unpaired presentations)
Number of subjects: 12
Study 7638220 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired test session
Number of subjects: 12
Study 2677410 — intervention group
Group type: EXPERIMENTAL
Intervention: Terodiline
Number of subjects: 70
Study 2677410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 343006 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg prazosin
Number of subjects: 24
Study 343006 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg prazosin
Number of subjects: 24
Study 31301668 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT ranibizumab (3 injections 0.5 mg)
Number of subjects: 60
Study 31301668 — intervention group
Group type: COMPARATOR
Intervention: IVT ranibizumab (1 injection 0.5 mg) + LP
Number of subjects: 60
Study 31301668 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone IVT implant (0.7 mg)
Number of subjects: 60
Study 31301668 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone IVT implant (0.7 mg) + LP
Number of subjects: 60
Study 28169458 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (BF) + home pelvic floor muscle training (PFMT)
Number of subjects: 72
Study 28169458 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 72
Study 28169458 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (BF)
Number of subjects: 72
Study 28169458 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback (BF) and Pelvic floor muscle training (PFMT)
Number of subjects: 72
Study 25456098 — intervention group
Group type: COMPARATOR
Intervention: T2DM patients
Number of subjects: 51
Study 25456098 — intervention group
Group type: COMPARATOR
Intervention: FCH patients
Number of subjects: 51
Study 23568174 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation M + OPV placebo
Number of subjects: 446
Study 23568174 — intervention group
Group type: COMPARATOR
Intervention: DTaP + OPV
Number of subjects: 446
Study 23568174 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations of DTaP-sIPV
Number of subjects: 446
Study 21751165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate pre-treatment (1.0 g/day for 6 days before and 3 days after radioiodine therapy)
Number of subjects: 128
Study 21751165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate pre-treatment
Number of subjects: 128
Study 21751165 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy with lithium carbonate pre-treatment
Number of subjects: 128
Study 21751165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lithium treatment)
Number of subjects: 128
Study 19847599 — intervention group
Group type: EXPERIMENTAL
Intervention: FGLM‐amide and SSSR eyedrops (n = 14)
Number of subjects: 29
Study 19847599 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered saline eyedrops (n = 15)
Number of subjects: 29
Study 16424409 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol, 42 mug bid via metered-dose inhaler (MDI)
Number of subjects: 26355
Study 16424409 — intervention group
Group type: COMPARATOR
Intervention: Placebo bid via metered-dose inhaler (MDI)
Number of subjects: 26355
Study 15274385 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/m2 plus docetaxel 90 mg/m2 every 3 weeks with prophylactic G‐CSF
Number of subjects: 25
Study 14517197 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem HCl ER tablets administered in the evening (360 mg single-dose and multiple-dose for 7 days)
Number of subjects: 48
Study 14517197 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem HCl ER tablets administered in the evening (360 mg once daily for 7 days)
Number of subjects: 48
Study 14517197 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem HCl ER tablets administered in the evening
Number of subjects: 48
Study 10200003 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV 0.1 mg
Number of subjects: 18
Study 10200003 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV 0.2 mg
Number of subjects: 18
Study 10200003 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV 0.4 mg
Number of subjects: 18
Study 10200003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7497198 — intervention group
Group type: EXPERIMENTAL
Intervention: Care in a stroke unit
Number of subjects: 10
Study 2156368 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with unprocessed wheat bran (30 g of dietary fiber)
Number of subjects: 17
Study 2156368 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 17
Study 2156368 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 17
Study 2156368 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate
Number of subjects: 17
Study 2156368 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with unprocessed wheat bran
Number of subjects: 17
Study 6932064 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.5 mg/kg)
Number of subjects: 10
Study 6932064 — intervention group
Group type: COMPARATOR
Intervention: Placebo elixir
Number of subjects: 10
Study 30799019 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app (Transplant Hero) and smart watch
Number of subjects: 0
Study 30799019 — intervention group
Group type: COMPARATOR
Intervention: Mobile app (Transplant Hero) only
Number of subjects: 0
Study 30799019 — intervention group
Group type: COMPARATOR
Intervention: Neither app nor smart watch
Number of subjects: 0
Study 28902533 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg
Number of subjects: 1538
Study 28902533 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg
Number of subjects: 1538
Study 28902533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1538
Study 25805187 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg + low-dose metformin (1000 mg)
Number of subjects: 689
Study 25805187 — intervention group
Group type: COMPARATOR
Intervention: High-dose metformin (2000 mg)
Number of subjects: 689
Study 25805187 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin + low-dose metformin (1000 mg)
Number of subjects: 689
Study 23856559 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (maximum dose 28 mg per day, titrated against bodyweight and adverse effects)
Number of subjects: 498
Study 23856559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 21855689 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-factor ergonomic intervention program
Number of subjects: 1480
Study 21855689 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized control group
Number of subjects: 1480
Study 19895777 — intervention group
Group type: COMPARATOR
Intervention: Assessment (n = 152)
Number of subjects: 446
Study 19895777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (n = 147)
Number of subjects: 446
Study 17470688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy with a platinum-based doublet followed by a single agent.
Number of subjects: 0
Study 17470688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential single agents.
Number of subjects: 0
Study 17470688 — intervention group
Group type: COMPARATOR
Intervention: Alternating chemotherapy strategy.
Number of subjects: 0
Study 17470688 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation/maintenance chemotherapy.
Number of subjects: 0
Study 15104322 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoluminescent dosemeters (TLD) used to assess operators' extremity doses during procedures
Number of subjects: 40
Study 15104322 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary occupational dose constraint value calculated from cardiologists' annual effective dose
Number of subjects: 40
Study 11279290 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 2
Study 11279290 — intervention group
Group type: EXPERIMENTAL
Intervention: Canavan disease group
Number of subjects: 2
Study 9041570 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone/Isolfurane anaesthetic
Number of subjects: 22
Study 9041570 — intervention group
Group type: COMPARATOR
Intervention: Propofol anaesthetic
Number of subjects: 22
Study 9041570 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 22
Study 7947876 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise echocardiography
Number of subjects: 51
Study 7947876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary ultrasonography
Number of subjects: 51
Study 7947876 — intervention group
Group type: COMPARATOR
Intervention: Coronary angiography
Number of subjects: 51
Study 29885911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular Botulinum toxin injections (30 units)
Number of subjects: 77
Study 27725121 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (30 minutes of bicycling)
Number of subjects: 42
Study 27725121 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (22 sessions)
Number of subjects: 42
Study 27725121 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (acute and prolonged)
Number of subjects: 42
Study 24638241 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 Gy
Number of subjects: 312
Study 24638241 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 Gy
Number of subjects: 312
Study 21979803 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) with an inspiratory load of 50% of maximal inspiratory pressure (Pi(max))
Number of subjects: 16
Study 21979803 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) with an inspiratory load of 15% of maximal inspiratory pressure (Pi(max))
Number of subjects: 16
Study 20203321 — intervention group
Group type: EXPERIMENTAL
Intervention: High NMES (60 minutes per day for 4 weeks)
Number of subjects: 66
Study 20203321 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NMES (30 minutes per day for 4 weeks)
Number of subjects: 66
Study 20203321 — intervention group
Group type: COMPARATOR
Intervention: Control (no NMES)
Number of subjects: 66
Study 19065894 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/d) and Bailing Capsule (2.0 g, twice a day)
Number of subjects: 84
Study 19065894 — intervention group
Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 84
Study 19065894 — intervention group
Group type: COMPARATOR
Intervention: Bailing Capsule alone
Number of subjects: 84
Study 19065894 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive agents (control)
Number of subjects: 84
Study 16648320 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000-lux light treatment and placebo capsule
Number of subjects: 96
Study 16648320 — intervention group
Group type: COMPARATOR
Intervention: 100-lux light treatment (placebo light) and fluoxetine, 20 mg/day
Number of subjects: 96
Study 12795792 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 504
Study 12795792 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 504
Study 10994615 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori IgG serology negative in patients aged 45 years or less
Number of subjects: 207
Study 10994615 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum pepsinogen I levels
Number of subjects: 207
Study 10994615 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of serum pepsinogen I assay and H. pylori IgG serology
Number of subjects: 207
Study 10994615 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal IgG serology and serum pepsinogen I
Number of subjects: 207
Study 10994615 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal blood tests
Number of subjects: 207
Study 9011452 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment (13-15 mg/kg/day for >3 months)
Number of subjects: 27
Study 9011452 — intervention group
Group type: COMPARATOR
Intervention: Untreated cholestatic patients
Number of subjects: 27
Study 9011452 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 healthy volunteers)
Number of subjects: 27
Study 9011452 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA treatment (38+/‐8 months)
Number of subjects: 27
Study 1601765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome
Number of subjects: 897
Study 1601765 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 897
Study 2869470 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg clorazepate dipotassium
Number of subjects: 24
Study 2869470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29974811 — intervention group
Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 9
Study 29974811 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 hours of fasting
Number of subjects: 9
Study 29974811 — intervention group
Group type: EXPERIMENTAL
Intervention: Three days of a hypercaloric high‐fat diet
Number of subjects: 9
Study 29570501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% at injection speed of 12 mL/h
Number of subjects: 60
Study 29570501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% at injection speed of 60 mL/h
Number of subjects: 60
Study 29570501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% at injection speed of 300 mL/h
Number of subjects: 60
Study 29570501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% at injection speed of 600 mL/h
Number of subjects: 60
Study 29570501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% at injection speed of 1800 mL/h
Number of subjects: 60
Study 29570501 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 26697890 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildronate injection 250 mg
Number of subjects: 0
Study 26697890 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildronate injection 500 mg
Number of subjects: 0
Study 26697890 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildronate injection 750 mg
Number of subjects: 0
Study 26697890 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose mildronate administration
Number of subjects: 0
Study 26697890 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall safety and tolerability of mildronate
Number of subjects: 0
Study 24608017 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstainers (n = 92)
Number of subjects: 179
Study 24608017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent smokers (n = 49)
Number of subjects: 179
Study 24608017 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent smokers (n = 38)
Number of subjects: 179
Study 24608017 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 179
Study 22658758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4073
Study 22658758 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher testosterone levels at baseline
Number of subjects: 4073
Study 22658758 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal baseline testosterone (≥10 nmol/l)
Number of subjects: 4073
Study 22658758 — intervention group
Group type: EXPERIMENTAL
Intervention: DHT levels
Number of subjects: 4073
Study 19369866 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glycerol (GLY)
Number of subjects: 654
Study 19369866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM)
Number of subjects: 654
Study 19369866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study 19369866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) and Oral glycerol (GLY)
Number of subjects: 654
Study 17683328 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of hydroxyzine (Atarax) 24 h preoperatively and 3.7 mg/kg hydroxyzine orally on the operation day
Number of subjects: 30
Study 17683328 — intervention group
Group type: COMPARATOR
Intervention: 3.7 mg/kg hydroxyzine orally only on the operation day
Number of subjects: 30
Study 15737255 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrodesis of first MTP joint
Number of subjects: 31
Study 15737255 — intervention group
Group type: COMPARATOR
Intervention: Mayo resection
Number of subjects: 31
Study 12196363 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM group)
Number of subjects: 835
Study 12196363 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus chemotherapy (TAM-CT group)
Number of subjects: 835
Study 9794557 — intervention group
Group type: EXPERIMENTAL
Intervention: Kimmelstiel Wilson nodules
Number of subjects: 36
Study 9794557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesangial sclerosis lesions
Number of subjects: 36
Study 7649959 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at doses of 0.3, 0.6, 0.9 mg/kg
Number of subjects: 40
Study 7649959 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 40
Study 7649959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2564785 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium
Number of subjects: 45
Study 2564785 — intervention group
Group type: COMPARATOR
Intervention: vecuronium or pancuronium
Number of subjects: 45